CALGB-50803 and RELEVANCE Trials of Lenalidomide and Rituximab in Previously Untreated Follicular Lymphoma


CALGB-50803 and RELEVANCE Trials of Lenalidomide and Rituximab in Previously Untreated Follicular Lymphoma
Slides from presentations at ICML 2013 and transcribed comments from a recent interview with Jonathan W Friedberg, MD, MMSc (7/19/13)
Martin P et al. CALGB 50803 (ALLIANCE): A Phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. Proc ICML 2013;Abstract 063.

Morschhauser F et al. The ‘RELEVANCE’ trial: A LYSA-sponsored Phase 3 randomized study to compare the efficacy and safety of rituximab plus lenalidomide versus rituximab plus any chemotherapy in subjects with previously untreated advanced follicular lymphoma. Proc ICML 2013;Abstract 136.

Dr Friedberg is Samuel Durand Professor of Medicine and Director of the Wilmot Cancer Center at the University of Rochester in Rochester, New York.